Skip to main content
. 2017 Aug 3;7:156. doi: 10.3389/fonc.2017.00156

Table 3.

Tumor-infiltrating lymphocytes (TILs) in residual disease post neoadjuvant treatment.

Trial Treatments Subtype n End points
Miyashita et al. (41)

  • Anthracycline

  • Taxane

 TNBC 131

  • CD8(+) TIL had strong prognostic significance for RFS: HR 3.09 (95% CI: 1.537–6.614, P = 0.0013)

  • CD8/FOXP3 ratio significantly correlated with RFS: HR 2.07 (95% CI: 1.029–4.436, P = 0.0412)
Dieci et al. (42)

  • Anthracycline

  • Taxane

  • Other

 TNBC 278

  • For each 10% increase in sTIL MFS HR 0.79 (95% CI: 0.71–0.88) and OS HR 0.79 (95% CI: 0.71–0.89), P < 0.001 for both outcomes

  • 5-year OS 91% (95% CI: 68–97%) for high-TIL patients, 55% (95% CI: 48–61%) for Low-TIL patients (HR 0.19, 95% CI: 0.06–0.61, P = 0.0017)
Loi et al. (43)

  • Doxorubicin

  • Cyclophosphamide

  • Paclitaxel

 TNBC 111 A strong positive linear association of TILs in NAC-treated specimens was observed with RFS (P = 0.0001, relative risk reduction of 3.4% for each 1% of TILs) and OS (P = 0.0016; relative risk reduction of 2.8% for each% of TILs)
Total patients 520

DFS, disease-free survival; MFS, metastases-free survival, NAC, neoadjuvant chemotherapy; OS, overall survival; RFS, recurrence free survival; sTIL, stromal TIL; TNBC, triple-negative breast cancer.